Review reveals improved drug delivery and targeting in cancer with melatonin and lactoferrin nanoparticles, indicating better therapeutic efficacy.
This review assesses the promise of nanoparticles containing melatonin and lactoferrin (ML-Lf-NPs) in treating cancer, concentrating on their capacity to improve drug delivery, pinpoint tumors, and optimize therapeutic efficacy. A thorough examination of recent progress in nanoparticle-oriented drug delivery systems was performed, highlighting the physicochemical characteristics, mechanisms of action, and biological interactions of ML-Lf-NPs. Melatonin nanoparticles demonstrate antioxidant and anti-inflammatory characteristics that enhance tumor targeting and therapeutic results. Lactoferrin nanoparticles show potential anticancer effects by improving cellular absorption and enabling targeted drug release at tumors. Both systems demonstrate considerable promise for enhancing drug bioavailability and minimizing side effects. ML-Lf-NPs signify creative strategies for cancer treatment. Their distinct characteristics allow for precise delivery and improved therapeutic effectiveness, opening doors for future clinical uses in cancer treatment. [Figure: see text].
No takes yet. Share an insight, caveat, or question.
Shah et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: